Magnesium Sulfate In Water Injection, Solution
NDC Package 0264-4205-52
Package Information
Magnesium Sulfate In Water (magnesium sulfate heptahydrate) injection is magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively. This formulation utilizes a injection, solution delivery system. Marketed by B. Braun Medical Inc., this product is identified by NDC 0264-4205 and is authorized under FDA application ANDA207967.
Identification & Billing
- RxCUI: 1658259 - magnesium sulfate 2 GM in 50 ML Injection
- RxCUI: 1658259 - 50 ML magnesium sulfate 40 MG/ML Injection
- RxCUI: 1658259 - magnesium sulfate 2 GM per 50 ML Injection
- RxCUI: 1658262 - magnesium sulfate 4 GM in 100 ML Injection
- RxCUI: 1658262 - 100 ML magnesium sulfate 40 MG/ML Injection
Clinical Specifications
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Inhibition Small Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Magnesium Ion Exchange Activity - [MoA] (Mechanism of Action)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Stimulation Large Intestine Fluid/Electrolyte Secretion - [PE] (Physiologic Effect)
Regulatory & Marketing
Hierarchy Structure
- 0264 - B. Braun Medical Inc.
- 0264-4205 - Magnesium Sulfate In Water
- 0264-4205-52 - 24 CONTAINER in 1 CASE / 50 mL in 1 CONTAINER
- 0264-4205 - Magnesium Sulfate In Water
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0264-4205-52 identifies a specific commercial package of 24 container in 1 case / 50 ml in 1 container of Magnesium Sulfate In Water, a human prescription drug labeled by B. Braun Medical Inc.. This injection, solution is formulated for intravenous use and contains magnesium sulfate heptahydrate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by B. Braun Medical Inc. on April 26, 2021. The current certification is valid through December 31, 2026.
How is this B. Braun Medical Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00264420552. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.